M
Martin Sebastian
Researcher at Goethe University Frankfurt
Publications - 90
Citations - 7495
Martin Sebastian is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 25, co-authored 74 publications receiving 5762 citations. Previous affiliations of Martin Sebastian include University of Mainz.
Papers
More filters
Journal ArticleDOI
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony Mok,Yi-Long Wu,Myung-Ju Ahn,Marina Chiara Garassino,Hye Ryoun Kim,Suresh S. Ramalingam,Frances A. Shepherd,Yong He,Hiroaki Akamatsu,Willemijn S. M. E. Theelen,Chee Khoon Lee,Martin Sebastian,A. Templeton,Helen Mann,Marcelo Marotti,Serban Ghiorghiu,Vassiliki A. Papadimitrakopoulou +16 more
TL;DR: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer as mentioned in this paper.
Journal ArticleDOI
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang,Yi-Long Wu,Martin Schuler,Martin Sebastian,Sanjay Popat,Nobuyuki Yamamoto,Caicun Zhou,Cheng Ping Hu,Kenneth J. O'Byrne,Jifeng Feng,Shun Lu,Yunchao Huang,Sarayut Lucien Geater,Kye Young Lee,Chun-Ming Tsai,Vera Gorbunova,Vera Hirsh,Jaafar Bennouna,S. M. Orlov,Tony Mok,Michael Boyer,Wu Chou Su,Ki Hyeong Lee,Terufumi Kato,Dan Massey,Mehdi Shahidi,Victoria Zazulina,Lecia V. Sequist +27 more
TL;DR: In this article, the effect of Afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials was evaluated.
Journal ArticleDOI
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Joel W. Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck +10 more
TL;DR: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipil optimumab in NSCLC.
Journal ArticleDOI
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Martin Reck,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Haolan Lu,J.-M. Cuillerot,Thomas J. Lynch +9 more
TL;DR: The results of this phase 2 study suggest further investigation of ipilimumab in ED-SCLC, and highlight the need for further investigation into the anti-CTLA4 monoclonal antibody.
Journal ArticleDOI
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
John V. Heymach,Luis Paz-Ares,Filippo de Braud,Martin Sebastian,David J. Stewart,Wilfried Eberhardt,Anantbhushan Ranade,Graham Lawrence Cohen,Jose Manuel Trigo,Alan B. Sandler,Philip Bonomi,Roy S. Herbst,Annetta D. Krebs,James Vasselli,Bruce E. Johnson +14 more
TL;DR: VPC could be safely administered to patients with NSCLC, including those with squamous cell histology and treated brain metastases, and meeting the prespecified study end point, whereas those receiving vandetanib monotherapy had shorter PFS.